These findings were reflected in an early report of an ongoing clinical study, where two COVID‐19 patients with ARDS began to improve only after treatment with recombinant anti‐C5a antibody (preprint: Gao et al, 2020). The gene discussed is C5AR1; the disease is acute respiratory distress syndrome.